.Nature Medication, Published online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) therapy of patients with HER2+ advanced bosom cancer cells and also energetic or stable human brain metastases revealed steady intracranial task as well as wide spread efficiency of T-DXd.